𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Scribed by Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F.; Milanowski, J.; Karnicka-Mlodkowski, H.; Pesek, M.; Serwatowski, P.; Ramlau, R.; Janaskova, T.; Vansteenkiste, J.; Strausz, J.; Manikhas, G. M.; Von Pawel, J.

Book ID
125515704
Publisher
American Society of Clinical Oncology
Year
2007
Tongue
English
Weight
169 KB
Volume
25
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase III Study of Erlotinib in Combinat
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. πŸ“‚ Article πŸ“… 2007 πŸ› American Society of Clinical Oncology 🌐 English βš– 169 KB

## Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, placebo-controlled, multicenter trial evaluated th